Hyperfine, Inc. key statistics and ratios
In fiscal 2025, Hyperfine, Inc. had return on equity of -79.0%, an operating margin of -273.4%, debt equal to 0.0% of equity and a current ratio of 4.34. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Gross margin | — | −78.0% | 13.3% | 43.1% | 45.7% | 49.8% | 51.4% |
| Operating margin | <−999% | <−999% | <−999% | −436.1% | −335.3% | −273.4% | −203.3% |
| Net margin | <−999% | <−999% | −649.2% | −401.0% | −315.9% | −262.3% | −210.8% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | −386.3% | −303.7% | −214.8% | −166.5% |
| Return on equity | — | −103.6% | −28.5% | −42.5% | −61.0% | −79.0% | −89.6% |
| Return on assets | −32.8% | −47.3% | −26.3% | −38.8% | −53.2% | −62.3% | −58.9% |
| Asset turnover | 0.00 | 0.01 | 0.04 | 0.10 | 0.17 | 0.24 | 0.28 |
| Current ratio | 16.60 | 12.55 | 14.62 | 10.14 | 6.15 | 4.34 | 6.15 |
| Debt to equity | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 36.0% |
| R&D as % of revenue | >999% | >999% | 413.2% | 203.9% | 174.5% | 128.7% | 94.2% |
| Capital spending as % of revenue | 533.3% | 181.2% | 8.6% | 7.3% | 3.0% | 8.7% | 2.8% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 52.4% | 35.6% | 41.3% | 49.3% | 53.8% | 50.9% | 50.7% | 50.7% |
| Operating margin | −300.9% | −463.8% | −510.2% | −355.9% | −259.5% | −144.9% | −219.3% | −216.9% |
| Net margin | −283.4% | −447.7% | −440.7% | −342.2% | −320.6% | −111.7% | −220.9% | −238.2% |
| Free-cash-flow margin | −238.2% | −360.4% | −454.9% | −312.7% | −166.2% | −99.6% | −237.0% | −186.9% |
| Current ratio | 6.44 | 6.15 | 6.07 | 5.02 | 3.63 | 4.34 | 5.52 | 6.15 |
| Debt to equity | — | — | — | — | — | 0.0% | 38.2% | 36.0% |
| R&D as % of revenue | 161.0% | 219.9% | 235.7% | 168.4% | 117.8% | 72.3% | 98.5% | 99.0% |
Financial health
- Short-term assets cover short-term liabilities $59m of assets due within a year against $10m of liabilities due within a year.
- Short-term assets cover long-term liabilities $59m short-term assets against $17m of longer-dated liabilities.
- More cash than debt $43m of cash against $13m of debt.
- Debt below 40% of shareholders' equity Debt is 36% of equity.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$27m of operating cash flow against $13m of debt.
- Operating profit covers interest at least five times over No material interest expense reported.
Moat
Weak moat
How hard Hyperfine's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -55.3% of total assets over 5 years.
- Pricing power 7 / 20
Gross margin has been a median 44.5%, moving by 27.3 percentage points (standard deviation) across 5 years.
- Durability 10 / 20
Operating margin has been a median -391.1%; its worst year was -2323.7%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 5 years, at a median -345.7% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- Sensus Healthcare, Inc. statistics
- Spectral AI, Inc. statistics
- Jin Medical International Ltd. statistics
- Nephros Inc statistics
- Vivos Therapeutics, Inc. statistics
Head to head: HYPR vs SRTSHYPR vs MDAIHYPR vs ZJYL
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies